Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Dr.-Volker-Sandig"

3 News Found

GeoVax secures multi-product license for ProBioGen's AGE1.CR.pIX suspension cell line
Drug Approval | September 27, 2023

GeoVax secures multi-product license for ProBioGen's AGE1.CR.pIX suspension cell line

The AGE1.CR.pIX cell line's versatility allows it to support a wide range of viruses and vaccine types

Nouscom reaches clinical phase II using ProBioGen’s AGE1.CR.pIX production platform
News | May 05, 2023

Nouscom reaches clinical phase II using ProBioGen’s AGE1.CR.pIX production platform

Nous-209 has been developed using the Nouscom's viral vector platform

ProBioGen co-develops new Freedom ExpiCHO-S cell line development kit
News | October 28, 2022

ProBioGen co-develops new Freedom ExpiCHO-S cell line development kit

It allows users to generate cell lines suitable for clinical development without their own starter cells, vectors or prior experience in the field.

Latest Stories

Vimta Labs posts Q4 FY25 PAT at Rs. 18.31 Cr

Sigachi Industries signs MoU with Respilon Group

USFDA inspects Marksans’s subsidiary Time-Cap Laboratories' manufacturing facility

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging